Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.
The conversation discusses hair loss treatments, specifically mentioning Spiro, Min, Fin, and RU. It highlights that Spiro is generally for women and can affect men's hormonal balance.
Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
A user is using homemade topical spironolactone for androgenetic alopecia and is unsure about its effectiveness due to concurrent telogen shedding. They are seeking advice on others' experiences with homemade topical spironolactone.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
A 26 year old female diagnosed with androgenetic alopecia who is interested in treatments such as spironolactone, finasteride and Minoxidil to help her hair loss but is worried about side effects like muscle gain, sex drive and effectiveness.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
A female user's experience using Spironolactone to treat Female Pattern Hair Loss (FPHL) and Androgenic Alopecia, as well as discussing the effectiveness of the drug at different dosages.
41-year-old female experienced slow hair thinning, took finasteride for a year, then switched to spironolactone. Irregular periods occurred, seeking advice on long-term side effects and considering a third medication.
The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.
Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.
PP405 shows promise for hair growth with significant results after 4 weeks, but skepticism exists due to its unavailability. Some users are hopeful for its potential, while others express concerns about side effects and market release delays.
A woman's experience with Spironolactone as treatment for female pattern hair loss, including the effects of increasing dosage and her doctor's recommendation to try finasteride if no results are seen after 6 months. Other users have also shared their experiences with using finasteride for this condition.
The conversation discusses hair loss treatments, including finasteride, minoxidil, estradiol, and spironolactone, with a focus on their effects on hair regrowth and gender transition. The original poster shares their personal experience with these treatments, emphasizing that estradiol and spironolactone should not be used by those who want to maintain a masculine appearance.
Treatment options for female alopecia androgenetica, discussing the availability of spironolactone online in The Netherlands and other potential treatments like finasteride, minoxidil and RU58841.
Hair loss treatments Fin and Minoxidil failed for user. Suggested alternatives are 75mg oral spiro and RU58841, but concerns about low testosterone and self-esteem were raised.
A 34-year-old woman is experiencing diffuse hair loss and irregular periods, possibly due to long-term spironolactone use. She is considering minoxidil and finasteride for treatment and seeking medical advice for androgenic alopecia and hormonal imbalances.
Spironolactone, finasteride, and dutasteride are discussed for hair maintenance, with concerns about testosterone and side effects like gynecomastia. Spironolactone is noted for use in both bodybuilding and hormone therapy, with low doses considered for minimizing side effects.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
The conversation discusses using oral spironolactone for hair loss in males when 5ari blockers fail. Concerns are raised about spironolactone's side effects, and alternatives like pyrilutamide and breezula are suggested.
PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.
User on 100mg spiro and oral minox for 2 years, now switching to dut due to low testosterone. Asks if tapering spiro is necessary or can stop immediately.
A user experienced facial swelling while taking spironolactone for androgenic alopecia, despite its diuretic properties. They are unsure about increasing the dose due to this side effect.